| Code | CSB-RA868278MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to mirikizumab, targeting the p19 subunit of interleukin-23 (IL23A). IL-23 is a heterodimeric cytokine that plays a critical role in inflammatory and immune responses by promoting the differentiation and survival of Th17 cells, which produce pro-inflammatory cytokines including IL-17. The IL-23/Th17 axis is implicated in the pathogenesis of various immune-mediated inflammatory diseases, particularly psoriasis, Crohn's disease, and ulcerative colitis, where aberrant IL-23 signaling contributes to chronic inflammation and tissue damage.
Mirikizumab is a humanized IgG4 monoclonal antibody that specifically binds to the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor and subsequent downstream inflammatory signaling. This biosimilar antibody serves as a valuable research tool for investigating IL-23-mediated pathways, studying mechanisms of inflammatory bowel disease and psoriatic disorders, evaluating therapeutic intervention strategies, and exploring the role of IL-23 in autoimmune disease models. It enables researchers to examine IL-23 blockade effects in various experimental systems.
There are currently no reviews for this product.